Primary and Secondary Virologic Outcomes Among Persons Randomized to IM or IV T-C or Placebo
REGRESSION
Abbreviations: aRR, adjusted risk ratio; LLOQ, lower limit of quantification (2.0 logIM administration consists of 600 mg (300 mg of each component) of monoclonal antibodies or 600 mg of placebo; IV administration, 300 mg (150 mg of each component) of monoclonal antibodies or 300 mg of placebo.Compares proportion of participants with SARS-CoV-2 RNA below LLOQ for tixagevimab-cilgavimab vs placebo, using a modified Poisson regression model adjusted for baseline logCalculated using the 2-sided Wald test.Calculated using the 2-sided Wilcoxon rank sum test.